Literature DB >> 15066292

Results of permanent prostate brachytherapy, 13 years of experience at a single institution.

Jan J Battermann1, Tom A Boon, Marinus A Moerland.   

Abstract

BACKGROUND AND
PURPOSE: To understand the influence of treatment techniques on the final outcome, as well as the relation of risk groups and of PSA nadir on the outcome, we reviewed our experience over more than 10 years. PATIENTS AND METHODS: Patients were treated in the period 1989 through 2000. Available for this evaluation are 351 patients. The distribution of cases by T stage was T1a, b (9%), T1c (49%), T2 (42%), and by grading G1 (58%), G2 (38%), G3 (1%) and Gx (3%). The technique of plantation of seeds varied over the years, starting with single seeds using a Mick applicator (104 patients), followed by Rapid strands without (70) and with pre-planning (177). Risk groups are categorised as low (iPSA <10 ng/ml, T1-2, grade 1), 116 patients; intermediate (iPSA 10-20 ng/ml, or grade 2-3), 114 patients; and high risk (both factors, or iPSA >20 ng/ml), 121 patients. The mean follow-up time was 50 months, median 48 and range 24-123 months.
RESULTS: Overall actuarial survival at 5 and 7 years was 85 and 76%, respectively. Forty patients died, eight (2%) because of or with prostate cancer. Alive are 310 patients (88%), with 223 patients bNED (71%), 51 (16%) with PSA failure, 21 (7%) with local and 15 (5%) with distant recurrence. Total bNED was 72%. Although results are better since the introduction of Rapid strands, 79% bNED versus 54% bNED for single seeds (P = 0.14) also the increase in activity per cm(3) prostate volume accounts for this improvement. With pre-planning a significant better result (P < 0.03) is obtained as compared to single seeds or strands without planning. Categorisation into risk groups results in a significant difference (P < 0.007) of bNED with risk factors, respectively, 57% for the high, 75% for the intermediate and 89% for the low risk group. Also PSA nadir had a significant effect on outcome; patients who reach a nadir of < or =0.5 ng/ml have a 91% chance of cure.
CONCLUSIONS: Results of permanent seed implantation improved with the introduction of strands, however, better staging and the increase in activity per cm(3) prostate volume also contributed to this improvement. A significant better result was obtained with pre-planning. Categorisation in risk groups corresponds very well with treatment outcome. Finally, a strong relation is found with PSA nadir.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066292     DOI: 10.1016/j.radonc.2004.01.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients.

Authors:  G Goldner; R Pötter; J J Battermann; M P Schmid; C Kirisits; S Sljivic; M van Vulpen
Journal:  Strahlenther Onkol       Date:  2012-02-22       Impact factor: 3.621

Review 2.  Recent developments and best practice in brachytherapy treatment planning.

Authors:  C D Lee
Journal:  Br J Radiol       Date:  2014-06-02       Impact factor: 3.039

3.  Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases.

Authors:  Harun Badakhshi; Reinhold Graf; Volker Budach; Peter Wust
Journal:  Strahlenther Onkol       Date:  2014-10-23       Impact factor: 3.621

4.  Brachytherapy for prostate cancer: a systematic review.

Authors:  Georgios Koukourakis; Nikolaos Kelekis; Vassilios Armonis; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2009-09-01

Review 5.  Current status and perspectives of brachytherapy for prostate cancer.

Authors:  Yasuo Yoshioka
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

6.  Low-dose rate brachytherapy of the prostate in elderly patients.

Authors:  C Chiumento; A Fiorentino; R Caivano; S Clemente; V Fusco
Journal:  Radiol Med       Date:  2012-09-17       Impact factor: 3.469

7.  [Permanent interstitial brachytherapy (seeds) for patients with primary localized prostate cancer: analysis of 100 patients].

Authors:  Gregor Goldner; Nevin Ozdemiroglu; Stefan Wachter; Thomas Hendrik Knocke; Richard Pötter
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients.

Authors:  Nikolaos Tselis; Ulf W Tunn; Georgios Chatzikonstantinou; Natasa Milickovic; Dimos Baltas; Markus Ratka; Nikolaos Zamboglou
Journal:  Radiat Oncol       Date:  2013-05-08       Impact factor: 3.481

Review 9.  Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Authors:  Edith D Canby-Hagino; Gregory P Swanson; E David Crawford; Joseph W Basler; Javier Hernandez; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

10.  International Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting.

Authors:  Eeva K Salminen; Krystyna Kiel; Geoffrey S Ibbott; Michael C Joiner; Eduardo Rosenblatt; Eduardo Zubizarreta; Jan Wondergem; Ahmed Meghzifene
Journal:  Radiat Oncol       Date:  2011-02-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.